Via Scoop.it – Demand Transformation
The Center for Immunotherapy at Roswell Park Cancer Institute has launched a phase I clinical research study of a dendritic cell vaccine designed to both eradicate cancer cells and prevent disease relapse. The new cell vaccine will be manufactured in the Institute’s new Therapeutic Cell Production Facility using a unique FDA-approved process — making RPCI the first research facility in the U.S. to use a custom-made barrier isolator for vaccine cell production, and the first in the world to use this system in an approved, government-regulated study.
Via nextbigfuture.com
Clinical trials for dendritic cell vaccine designed to both eradicate cancer cells and prevent disease relapse
Published in Demand Transformation
More from Demand TransformationMore posts in Demand Transformation »
- First they came for the Whistleblowers, and I did not speak out
- Message to My Senator Boxer: Uphold your Oath of Office: Squash Shadow Secret Gov’t
- Data Wants to be Free (as in Freedom)
- Self-Driving Cars: Biggest Societal Change Since… Cars
- Gigabit Internet for $70: the unlikely success of California’s Sonic.net WHY NOWHERE ELSE? Hint: Oligopoly